Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indian Vaccine Makers Face Loss Of WHO Sales By DGIC Delay

This article was originally published in PharmAsia News

Executive Summary

India's vaccine makers face loss of permission to sell their drugs to the United Nations because their National Regulatory Authority has not implemented Good Manufacturing Practices. The NRA is headed by the Drug Controller General of India. The WHO already had closed three public-sector Indian units because of noncompliance in January, but many more companies face the inability to have their vaccines pre-qualified for U.N. agencies and foundations that also require the designation. The WHO relies on Indian drug makers for as much as 80 percent of the vaccines it buys annually. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts